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Abstract
The cellular prion protein (PrPC) has been proposed to play an important role in the patho-
genesis of Alzheimer’s disease. In cellular models PrPC inhibited the action of the β-secre-
tase BACE1 on wild type amyloid precursor protein resulting in a reduction in amyloid-β
(Aβ) peptides. Here we have assessed the effect of genetic ablation of PrPC in transgenic
mice expressing human wild type amyloid precursor protein (line I5). Deletion of PrPC had
no effect on the α- and β-secretase proteolysis of the amyloid precursor protein (APP) nor
on the amount of Aβ38, Aβ40 or Aβ42 in the brains of the mice. In addition, ablation of PrPC
did not alter Aβ deposition or histopathology phenotype in this transgenic model. Thus
using this transgenic model we could not provide evidence to support the hypothesis that
PrPC regulates Aβ production.
Introduction
Alzheimer’s disease (AD) is the most common form of dementia affecting 30 million individu-
als world-wide [1,2]. Age is the greatest risk factor for AD, with the incidence doubling every 5
years after age 65. Therefore, with our ageing population, AD is placing immense financial and
social pressure on society. Currently there are no treatments that either cure or halt the pro-
gression of this neurodegenerative disease [3]. The majority (>95%) of AD cases have no
underlying genetic mutation and are referred to as sporadic or late-onset AD [4]. In a small
proportion of cases, mutations in the genes encoding the amyloid precursor protein (APP) or
presenilin (PS) 1 or PS2 give rise to early onset, familial AD [4]. The disease is characterised by
the deposition in the brain of extracellular plaques of amyloid-β (Aβ) which is derived from the
proteolytic processing of APP [5], along with intracellular neurofibrillary tangles of
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hyperphosphorylated tau protein [6]. APP is cleaved first by the β-secretase, β-site APP cleav-
ing enzyme-1 (BACE1), and then by the PS-containing γ-secretase complex to release Aβ, the
predominant forms of which are 40 or 42 amino acids in length (Aβ40 and Aβ42, respectively)
[5].
Cleavage of APP by BACE1 is the rate-limiting step in Aβ production [7] and various cellu-
lar proteins have been reported to influence this step, including the cellular form of the prion
protein (PrPC) [8]. PrPC inhibited the action of BACE1 on wild type APP (APPWT) in various
cellular models, in part through glycosaminoglycan-mediated interaction at the cell surface
and in part through retaining the pro-domain containing form of BACE1 in the early secretory
pathway [8,9]. In the brains of PrPC null mice there was a significant increase in the amount of
endogenous murine Aβ [8], consistent with PrPC having a role in regulating the production of
Aβ from APP in vivo. Together with the observation that PrPC was decreased in the brains
from sporadic AD individuals and that the amount of PrPC inversely correlated with BACE1
activity, soluble and insoluble Aβ and Braak stage in the human brain [10,11], led us to propose
that PrPC may function to protect against AD and that loss of PrPC would lead to the earlier
onset of AD [12,13].
The inhibitory effect of PrPC on the BACE1 cleavage of APP was only apparent on APPWT
and was lost on APP with the Swedish double point mutation adjacent to the BACE1 cleavage
site (APPSwe) [9]. APPSwe is subject to BACE1 cleavage in the secretory pathway [14,15] rather
than in the endosomal pathway as for APPWT [16,17]. As PrP
C interacted directly with the pro-
domain of the immature Golgi-localised form of BACE1, decreasing the amount of BACE1 at
the cell surface and in endosomes, this provided a mechanism to explain the differential inhibi-
tory effect of PrPC towards APPWT and APPSwe [9]. In transgenic mice expressing human
APPSwe.Ind we [9] and others [18–20] have reported that upon genetic ablation of PrP
C there is
no alteration in APP processing, Aβ levels or plaque pathology, consistent with this differential
inhibitory mechanism. Therefore, in this study we aimed to determine whether ablation of
PrPC in transgenic mice expressing human APPWT results in increased Aβ and subsequently
causes the premature appearance of plaque pathology.
Materials and Methods
Transgenic Animals
Transgenic APPWT mice over expressing human wild-type APP (line I5) or APPSwe,Ind mice
over expressing human APP with the Swedish (K670N/M671L) and Indiana (V717F) familial
AD mutations (line J20) [21] were obtained from The Jackson Laboratory, (Line B6.Cg-Tg
(PDGFB-APP)5Lms/J, stock number 004662 and B6.Cg-Tg(PDGFB-APPSwe,Ind)20Lms/2J,
stock number 006293, respectively) and The J. David Gladstone Institutes, San Francisco, CA
94158) and crossed with inbred PrP knockout mice (129Ola PrP-/-) [22]. The genetic back-
ground of all mice used in this study was mixed B6/129Ola and only female mice were used.
Operators were blinded to genotype and animals were randomly assigned to cages of n = 4 and
given access to food and water ad libitum. During housing, animals were monitored daily for
health status and no adverse effects were noted. All the transgenic mice used in this study were
genotyped. DNA was prepared from ear punch tissue using a DNeasy Kit (Qiagen). PCR was
performed using the protocol specific for these mice from The Jackson Laboratory. At end
point, animals were culled by cervical dislocation and brain hemispheres were either frozen at
-80°C for biochemical analysis or fixed in 10% formol saline for histopathological analysis.
These experiments were approved by The Roslin Institute’s Animal Welfare and Ethical
Review Board and were conducted according to the regulations of the UK Home Office Ani-
mals (Scientific Procedures) Act 1986. All efforts were made to minimise suffering.
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Homogenisation
Brain hemispheres were homogenised using a two-step extraction protocol [23]. Briefly, initial
homogenisation (120 mg/ml wet weight) was carried out using an electrical homogeniser in 2%
(w/v) SDS containing protease inhibitor cocktail (Roche Diagnostics GMbH, Germany) and
PhosSTOP phosphatase inhibitor (Roche Diagnostics GMbH, Germany), followed by centrifu-
gation at 100,000 g for 1 h at 4°C. The resultant supernatant (containing ‘soluble’ Aβ) was col-
lected and analysed as described below. The pellet was extracted in 70% (v/v) formic acid in
dH2O followed by centrifugation at 100,000 g for 1 h at 4°C. The supernatant (containing
‘insoluble’ Aβ) was collected and analysed as described below.
SDS-PAGE and Immunoblot Analysis
Samples were mixed with an equal volume of SDS dissociation buffer (125 mM Tris/HCl, pH
6.8, 2% (w/v) SDS, 20% (v/v) glycerol, 100 mM dithiothreitol, 0.002% (w/v) bromophenol
blue) and boiled for 5 min. Proteins from mouse brain homogenate (30 μg) were resolved by
SDS-PAGE using 7–17% polyacrylamide gradient gels. Resolved proteins were then transferred
to Immobilon P polyvinylidene difluoride membrane (Amersham, Little Chalfont, UK). The
membrane was blocked by incubation for 1 h with PBS containing 0.1% (v/v) Tween-20 and
5% (w/v) dried milk powder. Antibody incubations were performed in PBS-Tween containing
2% (w/v) BSA. Antibody 6D11 (Eurogentec Ltd., Liege, Belgium) recognises PrPC, antibody
Y188 (Abcam, Cambridge, UK) was used to detect full length APP and antibody AC15 (Sigma,
Dorset, UK) was used to detect actin. Horseradish peroxidase (HRP)-conjugated secondary
antibodies were used in the same buffer. Bound antibody was detected using the enhanced
chemiluminescence detection method (Amersham Biosciences, Amersham, UK).
Measurement of Aβ and Soluble APP Fragments by Mesoscale
Discovery Analysis
Biochemical analysis was performed on APPWT/PrP
+/+ (n = 3), APPWT/PrP
-/- (n = 6) mice at
32 and 75 weeks of age, and APPSwe,Ind/PrP
+/+ (n = 5, 7 and 4 at 5, 10 and 40 weeks, respec-
tively) Aβ peptides (Aβ38, Aβ40 and Aβ42) and soluble APP fragments (sAPPα and sAPPβ) con-
tained in the soluble (SDS extracted) fraction and Aβ peptides in the insoluble (formic acid
extracted) fraction were assessed using the Mesoscale Discovery (MSD) platform. Aβ38, Aβ40
and Aβ42 were measured using the V-Plex Aβ peptide panel (6E10) kit and sAPPα and sAPPβ
using the sAPPα/sAPPβmultiplex kit according to the manufacturer’s instructions (MSD,
Maryland US). SDS samples were diluted 1:40 and formic acid samples 1:500 in diluent 35.
Histology
Pathological analysis was performed on APPWT/PrP
+/+ (n = 4), APPWT/PrP
-/- (n = 4) and
APPSwe,Ind/PrP
+/+ (n = 4) mice at 32 and 75 weeks of age (the group size dropped to an n = 1 in
the 75 week APPWT/PrP
+/+ group due to intercurrent losses). Sections from a 129Ola (WT)
mouse at 75 weeks of age were also analysed. Neuropathologic evaluation was performed blind
by two operators. Fixed brain tissue was processed and tissue sections were prepared as
described [24]. Paraffin sections (6 μm) were stained with hematoxylin-eosin and immunos-
tained with the following antibodies: 4G8 (1/300) raised against Aβ17–24 (Covance; SIG-39200);
OC (1/500) that recognises a conformational-dependent epitope, specific to fibrils and soluble
fibrillar oligomers (a gift from Professor C. Glabe, Dept. Neurology, University of California at
Irvine School of Medicine, Irvine, CA, USA); anti-synaptophysin (1/150) that recognises a syn-
aptic vesicle protein (Synaptic systems, 101002); anti-glial fibrillary acidic protein (GFAP)
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(1/400) (DAKO Z0334); anti-Iba1 (1/1000) a calcium-binding protein specifically expressed in
macrophages and microglia (Wako 019–9741). Primary antibody binding was detected with
biotinylated goat anti-species specific IgG (Stratech Scientific Ltd.) and the Vectastain Elite
ABC Kit (Vector Laboratories), visualized with diaminobenzidine. For synaptophysin immu-
nolabelling antigen retrieval (DAKO S1699) and enhancement visualization system (EnVision™
K5007) were used. Antigen retrieval using 0.1M citrate buffer was performed with the Iba1
labelling.
Statistical Analysis
Densitometric analysis was performed using the advanced image data analyser (AIDA) pro-
gramme (Raytest Scientific Ltd). The Kolmogorov-Smirnov test was used to determine that the
data in each group was normally distributed. Following this the Levene’s test was used to
ensure that the data sets were of equal variance. In samples where the data met the criteria of a
normal distribution and equal variance, the parametric independent t-test was used to calculate
significance. In the samples which were not normally distributed the non-parametric two-
tailed Mann-Whitney U test was used to compare two independent samples. The data were
analysed using the Statistical Package for Social Sciences (SPSS 19) program (Chicago, USA).
Results and Discussion
In order to investigate whether ablation of PrPC in transgenic mice expressing human APPWT
results in increased Aβ, mice expressing human APPWT [21] were crossed with PrP
C-null
129/Ola mice [22]. Immunoblot analysis of mice at 32 and 75 weeks of age confirmed the
absence of PrPC in the APPWT/PrP
-/- mice and that the lack of PrPC had no effect on APP
expression (Fig 1A). The amounts of the soluble APP species, sAPPα and sAPPβ, were no dif-
ferent between the APPWT/PrP
-/- and APPWT/PrP
+/+ mice at either 32 or 75 weeks of age (Fig
1B), indicating that deletion of PrPC had no effect on either the α- or β-secretase cleavage of
APP. There was a significant increase in sAPPα in both genotypes at 75 weeks of age compared
to 32 weeks of age (Fig 1B) which resulted in an increased sAPPα:sAPPβ ratio (Fig 1C). The
levels of soluble (SDS-extracted) Aβ38, Aβ40 and Aβ42 were investigated. At both 32 and 75
weeks of age there was no difference in the amount of soluble Aβ38, Aβ40 or Aβ42 in the brain
homogenates of the APPWT/PrP
-/- mice compared to the APPWT/PrP
+/+ mice (Fig 1D). The
amount of Aβ40 and Aβ42 was higher at 75 weeks of age than at 32 weeks of age regardless of
Prnp genotype (Fig 1D), with a proportionately larger increase in Aβ42 such that the Aβ42: Aβ40
ratio increased in both the APPWT/PrP
-/- and APPWT/PrP
+/+ mice with age (Fig 1E). The levels
of Aβ peptides in the insoluble (formic acid extracted) fraction from either the APPWT/PrP
-/-
or the APPWT/PrP
+/+ mice were below the limit of detection in the assay. These data indicate
that lack of PrPC in transgenic mice expressing human APPWT does not alter the proteolysis of
APP or the levels of Aβ.
To investigate whether lack of PrPC in the APPWT/PrP
-/- mice affected the deposition of Aβ
in the brain, histopathological analysis of the hippocampus was carried out at 32 weeks of age
and compared to APPWT/PrP
+/+ mice. APPSwe,Ind/PrP
+/+ mice, which are known to accumu-
late limited Aβ-positive plaques at this age, were also analysed [9,21]. APPWT/PrP
+/+ and
APPWT/PrP
-/- mice at 32 weeks of age showed no obvious neuropathologic alterations (data
not shown). To explore whether histopathologic alterations were detected in older animals, we
also examined mice at 75 weeks of age. Histopathological analysis of WT, APPWT/PrP
+/+ and
APPWT/PrP
-/- mice at 75 weeks of age showed similar histopathologic features; i.e. absence of
obvious neuronal loss or other obvious alterations in the hippocampus proper or dentate gyrus
(Fig 2A, 2D and 2G) or 4G8 positive Aβ plaque formation (Fig 2B, 2E and 2H) in these mice.
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Fig 1. Ablation of PrPC does not affect APP proteolysis or Aβ peptide levels in APPWT mice. Brain hemispheres from 32 week and 75 week old
APPWT/PrP
+/+ and APPWT/PrP
-/- mice were subjected to two-step homogenisation, and the soluble proteins (SDS extracted) were subjected to
SDS-PAGE and immunoblotting. (A) representative immunoblots of PrPC and APP, with actin as a loading control. (B) Soluble (SDS extracted)
sAPPα and sAPPβ detected by MSD ELISA and (C) the ratio of sAPPα to sAPPβ. (D) Soluble (SDS extracted) Aβ38, Aβ40 and Aβ42 detected by
MSD ELISA and (E) the ratio of Aβ42 to Aβ40. Data shown as mean ± SEM (n = 3–6). There was no significant difference between the APPWT/PrP
+/+
and APPWT/PrP
-/- at the same time point for any of the APP or Aβ peptides.
doi:10.1371/journal.pone.0159119.g001
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We investigated whether the ablation of PrPC affected the level of Aβ fibrils and fibrillar oligo-
mers by using the OC antibody [25]. We observed that WT, APPWT/PrP
+/+ and APPWT/PrP
-/-
mice did not accumulate OC immunopositive deposits as shown by immunohistochemistry
(Fig 2C, 2F and 2I). As expected, in the APPSwe,Ind/PrP
+/+ mice at 75 weeks of age there was
disruption of the hippocampal structure with accumulation of 4G8 and OC positive Aβ deposi-
tion forming numerous uni and multicentric plaques (Fig 2J, 2K and 2L), as seen previously
[9]. Synapses are particularly vulnerable to the toxic effect of protein oligomers. Thus, we
Fig 2. Ablation of PrPC does not affect Aβ deposition in APPWT mice. Histopathologic analysis of the hippocampus of hematoxylin-eosin
stained sections of WT, APPWT/PrP
++ and APPWT/PrP
– mice show absence of obvious alterations in the pyramidal cell layer, stratum oriens and
lacunosum-molecular (A, D and G). No Aβ deposits are seen in sections probed with antibody 4G8 (B, E and H) or antibody OC (C, F and I). In
contrast, APPSwe,Ind/PrP
+/+ mice show plaques (arrows) in sections stained with hematoxylin-eosin (J) and abundant Aβ-reactive deposits in
sections probed with antibody 4G8 (K) and OC (L). All images x20 magnification and scale bar = 100μm.
doi:10.1371/journal.pone.0159119.g002
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performed immunostaining for the detection of the presynaptic protein synaptophysin and
observed disruption of immunoreactivity in 75 week old APPSwe,Ind/PrP
+/+ mice but not in
APPWT/PrP
+/+ or APPWT/PrP
-/- mice (Fig 3A, 3D and 3G). Glial markers (GFAP and Iba1)
showed similar intensity and pattern of reactivity in APPWT/PrP
+/+ and APPWT/PrP
-/- mice
(Fig 3B, 3C, 3E and 3F). In contrast, gliosis was observed particularly in the vicinity of amyloid
deposits in APPSwe,Ind/PrP
+/+ mice (Fig 3H and 3I). Thus, we did not detect any effect of PrPC
ablation on Aβ deposition using immunohistochemistry.
A comparison of the Aβ levels between the APPWT/PrP
+/+ mice at 75 weeks of age with
APPSwe,Ind/PrP
+/+ mice at 5 and 10 weeks (before significant Aβ deposition occurs) and at 40
weeks (after Aβ deposition in plaques appears) revealed that at 75 weeks of age the amount of
Aβ peptides in the soluble (SDS extracted) fraction of the APPWT/PrP
+/+ mice was comparable
to the amount of each peptide in the 5 week old APPSwe,Ind/PrP
+/+ mice (Fig 4A). Although
Aβ40 and Aβ42 were readily detectable in the insoluble (formic acid extracted) fraction from the
APPSwe,Ind/PrP
+/+ mice (Fig 4B), no Aβ was detected in the insoluble fraction from the
APPWT/PrP
+/+ mice. The soluble Aβ42:Aβ40 ratio increased with age in both APPWT/PrP
+/+
Fig 3. Ablation of PrPC does not affect synaptophysin immunoreactivity and does not induce gliosis in APPWT mice. APPWT/PrP
+/+ and
APPWT/PrP
-/- mice show retention of the pre-synaptic marker synaptophysin (A, D) while APPSwe.Ind/PrP
+/+ mice reveal disorganization of
synaptophysin immunoreactivity (arrow) (G). Astrogliosis and microgliosis are observed in 75 week old APPSwe.Ind/PrP
+/+ mice, (arrows) (H, I) but not
in mice expressing APPWT/PrP
+/+ and APPWT/PrP
-/- (B, C, E, F). Section were probed with anti-synaptophysin (A, D, G), anti-GFAP (B, E, H), and anti-
Iba1 (C, F, I) antibodies. Figures A,D,G (synaptophysin) x60 magnification scale bar = 20μm, figures B,E,H (GFAP) and C,F,I (Iba1) x40 magnification
scale bar = 50μm.
doi:10.1371/journal.pone.0159119.g003
Ablation of Prion Protein Does Not Alter APP Proteolysis, Amyloid-β Levels or Pathologic Phenotype
PLOS ONE | DOI:10.1371/journal.pone.0159119 July 22, 2016 7 / 10
Fig 4. Comparison of Aβ levels in APPWT and APPSwe.Ind mice. Brain hemispheres from 75 week old
APPWT/PrP
+/+ and from 5, 10 and 40 week old APPSwe,Ind/PrP
+/+ mice were subjected to two-step
homogenisation. (A) Soluble (SDS extracted) and (B) insoluble (formic acid extracted) Aβ38, Aβ40 and Aβ42
detected by MSD ELISA and (C) the ratio of Aβ42:Aβ40. Data shown as mean ± SEM (n = 3–6), * p<0.05
compared to the 75 week old APPWT/PrP
+/+ group.
doi:10.1371/journal.pone.0159119.g004
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and APPSwe,Ind/PrP
+/+ mice (Fig 4C) but was significantly higher in the APPSwe,Ind/PrP
+/+ mice
than in the APPWT/PrP
+/+ mice consistent with the presence of the Indiana mutation increas-
ing production of Aβ42 as observed previously [21]. Even at 75 weeks of age the amount of
Aβ42 in the APPWT/PrP
+/+ mice is significantly lower than that in the APPSwe,Ind/PrP
+/+ mice
at 5, 10 and 40 weeks of age (Fig 4A). Thus in the APPWT/PrP
+/+ mice even at 75 weeks of age
the low level of Aβ42 is likely below the threshold required for deposition to occur.
Conclusion
In cellular models PrPC differentially affected the activity of the β-secretase BACE1 towards
APPWT and APPSwe, inhibiting the processing of the former but having no effect on the cleav-
age of the latter [8,9]. Thus we undertook this study in order to investigate the effect of genetic
ablation of PrPC on human APPWT processing in vivo. In contrast to the cellular models, lack
of PrPC had no effect on the α- and β-secretase proteolysis of APP or on the amount of Aβ pep-
tides in the brains of mice expressing human APPWT. Also we did not detect any Aβ deposition
as shown by immunohistochemistry in the mice lacking PrPC as compared to those with a nor-
mal level of the protein. In the human brain the amount of PrPC inversely correlated with
BACE1 activity, soluble and insoluble Aβ and Braak stage [11], consistent with levels of PrPC
affecting APP processing and Aβ production. However, we could find no evidence that loss of
PrPC affected APP proteolysis, Aβ levels or plaque pathology in vivo in transgenic mice
expressing human APPWT. Whether this reflects a difference in the role of PrP
C in regulating
APP processing and Aβ production between this transgenic mouse model and the situation in
the human brain will require further study.
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